HpElectronPic700x180P

幽门螺菌研究重要相关参考文献

1. Hunt RH, Xiao SD, Megraud F, et al. Helicobacter pylori in developing countries. World Gastroenterology Organisation Global Guideline. J Gastrointestin Liver Dis. 2011, 20(3): 299-304.
2. Lam SK, Talley NJ. Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol. 1998, 13(1): 1-12.
3. Fock KM, Katelaris P, Sugano K, et al. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol. 2009, 24(10): 1587-600.
4. The European Helicobacter pylori study group (EH.PYLORISG). Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. Gut, 1997, 41: 8–13.
5. Malfertheiner P, Megraud F, O’Morain C, et al. The uropean Helicobacter pylori Study Group (EH.PYLORISG). Current concept in the management of Helicobacter pylori infection. The Maastricht 2–2000 Consensus Report. Aliment Pharmacol Ther, 2002, 16: 167–180.
6. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut, 2007, 56: 772-781.
7. Malfertheiner P, Megraud F, O'Morain C, et al. Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut, 2012, 61: 646-664.
8. 全国幽门螺杆菌科研协作组. 幽门螺杆菌若干问题的共识意见. 中华医学杂志, 2000, 80: 394-395.
9. 胡伏莲. 对幽门螺杆菌若干问题的共识意见 (2003•中国). 中华医学杂志, 2004,84:522-523.
10. 中华医学会消化病分会幽门螺杆菌学组/全国幽门螺杆菌研究协作组. 第三次全国幽门螺杆菌感染若干问题共识报告. 中华医学杂志, 2008, 88:652-656.
11. 中华医学会消化病分会幽门螺杆菌学组/全国幽门螺杆菌研究协作组. 第四次全国幽门螺杆菌感染处理共识报告. 中华内科杂志, 2012, 51: 832-837.
12. 血清抗体检测幽门螺杆菌全国多中心临床研究协作组. 含现症感染条带血清抗体检测幽门螺杆菌现症感染的多中心临床研究. 中华医学杂志. 2011, 91(27): 1891-1894.
13. 周丽雅,林三仁,丁士刚,等. 根除幽门螺杆菌对胃癌患病率及胃黏膜组织学变化的八年随访研究. 中华消化杂志,2005, 25(6): 324-327.
14. 舒徐,吕农华,祝荫,等. 根除幽门螺杆菌对胃窦黏膜萎缩和肠上皮化生逆转影响的前瞻性研究. 中华消化杂志,2009, 29(12):799-802.
15. 金珠,肺三仁,沈祖尧,等. 根除幽门螺杆菌对胃黏膜肠化的影响. 中华消化杂志,2003., 23(3): 161-164.
16. 李晓波,戈之铮,陈晓宇,等. 功能性消化不良根除幽门螺杆菌后症状改善相关因素分析. 中华消化内镜杂志,2006, 23(2):09-113.
17. 胡品津,曾志荣,林汉良,等. 幽门螺杆菌的根除与萎缩性胃炎形成和逆转的动物实验研究. 中华消化杂志,2000, 20(3): 155-158.
18. 李晓波,戈之铮,陈晓宇,等. 功能性消化不良根除幽门螺杆菌后症状改善相关因素分析. 中华消化内镜杂志, 2006, 23(2).
19. 成虹,胡伏莲,张国新,等. 含左氧氟沙星三联疗法一线治疗幽门螺杆菌感染:多中心随机对照临床研究. 中华医学杂志, 2010, 90(2), 79-82.
20. Lang L. Barry Marshall. 2005 Nobel laureate in medicine and physiology. Gastroenterology, 2005, 129: 1813-1814.
21. Moayyedi P, Soo S, Deeks J, et al. Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. Dyspepsia Review Group. BMJ, 2000, 321: 659-664.
22. Jin X, Li YM. Systematic review and meta-analysis from Chinese literature: the association between Helicobacter pylori eradication and improvement of functional dyspepsia. Helicobacter, 2007, 12: 541-546.
23. Correa P, Houghton J.Carcinogenesis of Helicobacter pylori. Gastroenterology, 2007, 133: 659-672.
24. Rokkas T, Pistiolas D, Sechopoulos P, et al. The long-term impact of Helicobacter pylori eradication on gastric histology: a systematic review and meta-analysis. Helicobacter,2007,12 (Suppl 2): 32-38.
25. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med, 1996, 334: 1018-1022.
26. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet, 2002,3 59: 14-22.
27. Yuan W, Li Yumin, Yang Kehu, et al. Iron deficiency anemia in Helicobacter pylori infection: meta-analysis of randomized controlled trials. Scand J Gastroenterol, 2010, 45: 665-676.
28. Stasi R, Sarpatwari A, Segal JB, et al. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review. Blood, 2009, 113: 1231-1240.
29. Li XB, Liu WZ, Ge ZZ, et al. Helicobacter pylori “test-and-treat” strategy is not suitable for the management of patients with uninvestigated dyspepsia in Shanghai. Scand J Gastroenterol, 2005, 40: 1028-1031.
30. Qian B, Ma S, Shang L, et al. Effects of Helicobacter pylori eradication on gastroesophageal reflux disease. Helicobacter, 2011, 16:255-265.
31. Nam SY, Choi IJ, Ryu KH, et al. Effect of Helicobacter pylori infection and its eradication on reflux esophagitis and reflux symptoms. Am J Gastroenterol, 2010, 105: 2153-2162.
32. 张万岱, 胡伏莲, 萧树东, 等. 中国自然人群幽门螺杆菌感染的流行病学调查. 现代消化及介入诊疗, 2010, 15: 265-270.
33. 中华医学会消化病学分会幽门螺杆菌学组/全国幽门螺杆菌科研协作组,成虹,胡伏莲,谢勇,等. 中国幽门螺杆菌耐药状况以及耐药对治疗的影响——全国多中心临床研究. 胃肠病学, 2007, 12: 525-530.
34. Sun QJ, Liang X, Zheng Q, et al. Resistance of Helicobacter pylori to antibiotics from 2000 to 2009 in Shanghai. World J Gastroenterol, 2010, 16: 5118-5121.
35. Yan X, Zhou L, Song Z, et al. Sequential therapy for Helicobacter pylori eradication in adults compared with triple therapy in china: a multiplecenter, Prospective, randomized, controlled trial (abstract). Helicobacter, 2011, 16 (Suppl 1): 87.
36. Mégraud F. The challenge of Helicobacter pylori resistance to antibiotics: the comeback of bismuth-based quadruple therapy. Therap Adv Gastroenterol, 2012, 5: 103-109.
37. Baker DE. Pylera plus omeprazole: quadruple treatment for Helicobacter pylori. Rev Gastroenterol Disord, 2008, 8: 33-41.
38. Fischbach LA, van Zanten S, Dickason J. Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies. Aliment Pharmacol Ther, 2004, 20: 1071-1082.
39. 牟方宏, 胡伏莲, 杨桂彬, 等. 质子泵抑制剂四联疗法作为幽门螺杆菌根除治疗一线方案的临床研究. 胃肠病学,2007, 12: 531-534.
40. 徐美华, 张桂英, 李常娟. 含铋剂四联一线治疗方案根除幽门螺杆菌疗效观察.浙江大学学报(医学版), 2011, 40: 327-331.
41. Gu LY, Lin WW, Lu H, et al. Quadruple therapy with medications containing either rufloxacin or furazolidone as a rescue regimen in the treatment of Helicobacter pylori-infected dyspepsia patients: a randomized pilot study. Helicobacter, 2011, 16: 284-288.
42. Minakari M, Davarpanah Jazi AH, Shavakhi A, et al. A randomized controlled trial: efficacy and safety of azithromycin, ofloxacin, bismuth, and omeprazole compared with amoxicillin, clarithromycin, bismuth, and omeprazole as second-line therapy in patients with Helicobacter pylori infection. Helicobacter, 2010, 15: 154-159.
43. 王震华,熊光苏,吴叔明. 含左氧氟沙星的四联方案补救治疗幽门螺杆菌的临床研究. 胃肠病学和肝病学杂志, 2006, 15: 38-39.
44. Hunfeld NG, Touw DJ, Mathot RA, et al. A comparison of the acid-inhibitory effects of esomeprazole and rabeprazole in relation to pharmacokinetics and CYP2C19 polymorphism. Aliment Pharmacol Ther, 2012, 35: 810-818.
45. Anagnostopoulos GK, Tsiakos S, Margantinis G, et al. Esomeprazole versus omeprazole for the eradication of Helicobacter pylori infection: results of a randomized controlled study. J Clin Gastroenterol, 2004, 38: 503-506.
46. Vaira D, Malfertheiner P, Megraud F, et al. Diagnosis of Helicobacter pylori infection with a new non-invasive antigen-based assay. H.pyloriSA European study group. Lancet 1999; 354: 30–33.
47. Chiba N, Van Zanten SJ, Sinclair P, et al. Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment-Helicobacter pylori positive (CADET-H.pylori) randomised controlled trial. BMJ, 2002, 324: 1012–16.
48. Maconi G, Sainaghi M, Molteni M, et al. Predictors of long-term outcome of functional dyspepsia and duodenal ulcer after successful Helicobacter pylori eradication–a 7-year follow-up study. Eur J Gastroenterol Hepatol, 2009, 21: 387 – 93.
49. Gwee KA, Teng L, Wong RK, et al. The response of Asian patients with functional dyspepsia to eradication of Helicobacter pylori infection. Eur J Gastroenterol Hepatol, 2009, 21: 417–24.
50. Yaghoobi M, Farrokhyar F, Yuan Y, et al. Is there an increased risk of GERD after Helicobacter pylori eradication?: a meta-analysis. Am J Gastroenterol, 2010, 105: 1007–1013.
51. de Leest HT, Steen KS, Lems WF, et al. Eradication of Helicobacter pylori does not reduce the incidence of gastroduodenal ulcers in patients on long-term NSAID treatment: double-blind, randomized, placebo-controlled trial. Helicobacter, 2007, 12: 477–485.
52. Vergara M, Catalan M, Gisbert JP, et al. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther, 2005, 21: 1411–1418.
53. Chan F, Ching J, Suen B, et al. H. pylori eradication on the long-term incidence of recurrent ulcer bleeding in high-tisk aspirin users: a 10-year prospective cohort study (abstr). Gastroenterology, 2011, 140: S173–174.
54. Lundell L, Havu N, Miettinen P, et al. Changes of gastric mucosal architecture during long-term omeprazole therapy: results of a randomized clinical trial. Aliment Pharmacol Ther, 2006, 23: 639–47.
55. Hagiwara T, Mukaisho K, Nakayama T, et al. Long-term proton pump inhibitor administration worsens atrophic corpus gastritis and promotes adenocarcinoma development in Mongolian gerbils infected with Helicobacter pylori. Gut, 2011, 60: 624–630.
56. Fox JG, Kuipers EJ. Long-term proton pump inhibitor administration, H pylori and gastric cancer: lessons from the gerbil. Gut, 2011, 60: 567–568.
57. Malfertheiner P, Sipponen P, Naumann M, et al. Helicobacter pylori eradication has the potential to prevent gastric cancer: a state-of-the-art critique. Am J Gastroenterol, 2005, 100: 2100–2115.
58. Wong BC, Lam SK, Wong WM, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA, 2004, 291: 187–194.
59. Wang J, Xu L, Shi R, et al. Gastric atrophy and intestinal metaplasia before and after Helicobacter pylori eradication: a meta-analysis. Digestion, 2011, 83: 253 – 260.
60. Wotherspoon AC, Doglioni C, Diss TC, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet, 1993, 342: 575–577.
61. Chen LT, Lin JT, Tai JJ, et al. Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma. J Natl Cancer Inst, 2005, 97: 1345–1353.
62. Stathis A, Chini C, Bertoni F, et al. Long-term outcome following Helicobacter pylori eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type. Ann Oncol, 2009, 20: 1086–1093.
63. Wundisch T, Thiede C, Morgner A, et al. Long-term follow-up of gastric MALTlymphoma after Helicobacter pylori eradication. J Clin Oncol, 2005, 23: 8018 – 8024.
64. Ruskone-Fourmestraux A, Fischbach W, Aleman BM, et al. EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT. Gut, 2011, 60: 747–758.
65. Qu XH, Huang XL, Xiong P, et al. Does Helicobacter pylori infection play a role in iron deficiency anemia? A meta-analysis. World J Gastroenterol, 2010, 16: 886–896.
66. Muhsen K, Cohen D. Helicobacter pylori infection and iron stores: a systematic review and meta-analysis. Helicobacter, 2008, 13: 323–340.
67. Ioannou GN, Weiss NS, Kearney DJ. Is Helicobacter pylori seropositivity related to body mass index in the United States? Aliment Pharmacol Ther, 2005, 21: 765–772.
68. Lahner E, Annibale B, Delle FG. Systematic review: helicobacter pylori infection and impaired drug absorption. Aliment Pharmacol Ther, 2009, 29: 379–386.
69. Bugdaci MS, Zuhur SS, Sokmen M, et al. The role of Helicobacter pylori in patients with hypothyroidism in whom could not be achieved normal thyrotropin levels despite treatment with high doses of thyroxine. Helicobacter, 2011, 16: 124–130.
70. Basso D, Zambon CF, Letley DP, et al. Clinical relevance of H. pylori cagA and vacA gene polymorphisms. Gastroenterology, 2008, 135: 91–99.
71. Schmidt H, Ha D, Tayler E, et al. Variation in human genetic polymorphisms, their association with H. pylori acquisition and gastric cancer in a multi-ethnic country. J Gastroenterol Hepatol, 2011, 26:1725–1732.
72. Gisbert JP, Pajares JM. Review article: 13C-urea breath test in the diagnosis of Helicobacter pylori infection—a critical review. Aliment Pharmacol Ther, 2004, 20: 1001–1017.
73. Gisbert JP, de la MF, Abraira V. Accuracy of monoclonal stool antigen test for the diagnosis of H. pylori infection: a systematic review and meta-analysis. Am J Gastroenterol, 2006, 101: 1921–1930.
74. Deguchi R, Matsushima M, Suzuki T, et al. Comparison of a monoclonal with a polyclonal antibody-based enzyme immunoassay stool test in diagnosing Helicobacter pylori infection after eradication therapy. J Gastroenterol, 2009, 44: 713–716.
75. Shimoyama T, Kato C, Kodama M, et al. Applicability of a monoclonal antibody-based stool antigen test to evaluate the results of Helicobacter pylori eradication therapy. Jpn J Infect Dis, 2009, 62: 225–227.
76. Calvet X, Lario S, Ramirez-Lazaro MJ, et al. Accuracy of monoclonal stool tests for determining cure of Helicobacter pylori infection after treatment. Helicobacter, 2010, 15: 201–205.
77. Schwarzer A, Lottspeich C, Russmann H, et al. Evaluation of a novel rapid one-step monoclonal chromatographic immunoassay for detection of Helicobacter pylori in stool from children. Eur J Clin Microbiol Infect Dis, 2007, 26: 475–480.
78. Levine A, Shevah O, Shabat-Sehayek V, et al. Masking of 13C urea breath test by proton pump inhibitors is dependent on type of medication: comparison between omeprazole, pantoprazole, lansoprazole and esomeprazole. Aliment Pharmacol Ther, 2004, 20: 117–122.
79. Shirin H, Levine A, Shevah O, et al. Eradication of Helicobacter pylori can be accurately confirmed 14 days after termination of triple therapy using a high-dose citric acid-based 13C urea breath test. Digestion, 2005, 71: 208–212.
80. Gisbert JP, Pajares JM. 13C-urea breath test in the management of Helicobacter pylori infection. Dig Liver Dis, 2005, 37: 899–906.
81. Megraud F. Helicobacter pylori and antibiotic resistance. Gut, 2007, 56: 1502.
82. Wenzhen Y, Yumin L, Quanlin G, et al. Is antimicrobial susceptibility testing necessary before first-line treatment for Helicobacter pylori infection? Meta-analysis of randomized controlled trials. Intern Med, 2010, 49: 1103–1109.
83. Woo HY, Park DI, Park H, et al. Dual-priming oligonucleotide-based multiplex PCR for the detection of Helicobacter pylori and determination of clarithromycin resistance with gastric biopsy specimens. Helicobacter, 2009, 14: 22–28.
84. Gatta L, Vakil N, Leandro G, et al. Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. Am J Gastroenterol, 2009, 104: 3069–79.
85. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut, 2010, 59: 1143–53.
86. Gisbert JP, Calvet X, O'Connor A, et al. Sequential therapy for Helicobacter pylori eradication: a critical review. J Clin Gastroenterol, 2010, 44: 313–25.
87. Vaira D, Zullo A, Vakil N, et al. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. Ann Intern Med, 2007, 146: 556–63.
88. Essa AS, Kramer JR, Graham DY, et al. Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing “concomitant therapy” versus triple therapy for Helicobacter pylori eradication. Helicobacter, 2009, 14: 109–18.
89. Gisbert JP, Calvet X. Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori. Aliment Pharmacol Ther, 2011, 34: 604–17.
90. Malfertheiner P, Bazzoli F, Delchier JC, et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazoleand tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet, 2011, 377: 905–13.
91. Padol S, Yuan Y, Thabane M, et al. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis. Am J Gastroenterol, 2006, 101: 1467–75.
92. Furuta T, Sugimoto M, Shirai N. Effect of MDR1 C3435T polymorphism on cure rates of Helicobacter pylori infection by triple therapy with lansoprazole, amoxicillin and clarithromycin in relation to CYP 2C19 genotypes and 23S rRNA genotypes of H. pylori. Aliment Pharmacol Ther, 2007, 26: 693–703.
93. Villoria A. Acid-related diseases: are higher doses of proton pump inhibitors more effective in the treatment of Helicobacter pylori infection? Gastroenterol Hepatol, 2008, 31: 546–7.
94. Calvet X, Garcia N, Lopez T, et al. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther, 2000, 14: 603–9.
95. Fuccio L, Minardi ME, Zagari RM, et al. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Intern Med, 2007, 147: 553–62.
96. Gisbert JP, Gonzalez L, Calvet X, et al. Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori. Aliment Pharmacol Ther, 2000, 14: 1319–28.
97. Zou J, Dong J, Yu X. Meta-analysis: Lactobacillus containing quadruple therapy versus standard triple first-line therapy for Helicobacter pylori eradication. Helicobacter, 2009, 14: 97–107.
98. Sachdeva A, Nagpal J. Meta-analysis: efficacy of bovine lactoferrin in Helicobacter pylori eradication. Aliment Pharmacol Ther, 2009, 29: 720–30.
99. Tong JL, Ran ZH, Shen J, et al. Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther, 2007, 25: 155–68.
100. Sachdeva A, Nagpal J. Effect of fermented milk-based probiotic preparations on H. pylori eradication: a systematic review and meta-analysis of randomized-controlled trials. Eur J Gastroenterol Hepatol, 2009, 1:45–53.
101. Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther, 2010, 32: 1069–79.
102. Gisbert JP, Gisbert JL, Marcos S, et al. Empirical rescue therapy after Helicobacter pylori treatment failure: a 10-year single-centre study of 500 patients. Aliment Pharmacol Ther, 2008, 27:346–54.
103. Lee BH, Kim N, Hwang TJ, et al. Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate in Korea. Helicobacter, 2010, 15: 38–45.
104. Luther J, Higgins PD, Schoenfeld PS, et al. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol, 2010, 105: 65 –73.
105. Gisbert JP, Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther, 2006, 23: 35–44.
106. Saad RJ, Schoenfeld P, Kim HM, et al. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am J Gastroenterol, 2006, 101: 488–96.
107. Cammarota G, Martino A, Pirozza G, et al. High efficacy of 1-week doxycyline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for H. pylori infection. Aliment Pharmacol Ther, 2004, 19: 789–95.
108. Ford AC, Malfertheiner P, Giguere M, et al. Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis. World J Gastroenterol, 2008, 14: 7361–70.
109. Rodriguez-Torres M, Salgado-Mercado R, Rios-Bedoya CF, et al. High eradication rates of Helicobacter pylori infection with first- and second-line combination of esomeprazole, tetracyclin and metronidazole in patients allergic to penicillin. Dig Dis Sci, 2005, 50: 634–9.
110. Gisbert JP, Perez-Aisa A, Castro-Fernandez M, et al. Helicobacter pylori first-line treatment and rescue option containing levofloxacin in patients allergic to penicillin. Dig Liver Dis, 2010, 42: 287–90.
111. Gisbert JP, Pajares JM. Systematic review and meta-analysis: is 1-week proton pump inhibitor-based triple therapy sufficient to heal peptic ulcer? Aliment Pharmacol Ther, 2005, 21: 795–804.
112. Sung JJ. Marshall and Warren Lecture 2009: peptic ulcer bleeding: an expedition of 20 years from 1989-2009. J Gastroenterol Hepatol, 2010, 25: 229 – 33.
113. van Leerdam ME. Epidemiology of acute upper gastrointestinal bleeding. Best Pract Res Clin Gastroenterol, 2008, 22: 209–24.
114. Gisbert JP, Abraira V. Accuracy of Helicobacter pylori diagnostic tests in patients with bleeding peptic ulcer: a systematic review and meta-analysis. Am J Gastroenterol, 2006, 101: 848–63.
115. Sanchez-Delgado J, Gene E, Suarez D, et al. Has H. pylori prevalence in bleeding peptic ulcer been underestimated? A meta-regression. Am J Gastroenterol, 2011, 106: 398–405.
116. Gisbert JP, Esteban C, Jimenez I, et al. 13C-urea breath test during hospitalization for the diagnosis of Helicobacter pylori infection in peptic ulcer bleeding. Helicobacter, 2007, 12: 231–7.
117. Barkun AN, Bardou M, Kuipers EJ, et al. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med, 2010, 152: 101–13.
118. Asaka M, Kato M, Takahashi S, et al. Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter, 2010, 15: 1–20.
119. Fock KM, Talley N, Moayyedi P, et al. Asia-Pacific consensus guidelines on gastric cancer prevention. J Gastroenterol Hepatol, 2008, 23: 351–65.
120. Malfertheiner P, Bornschein J, Selgrad M. Role of Helicobacter pylori infection in gastric cancer pathogenesis: a chance for prevention. J Dig Dis, 2010, 11: 2–11.
121. Bornschein J, Selgrad M, Warnecke M, et al. H. pylori infection is a key risk factor for proximal gastric cancer. Dig Dis Sci, 2010, 55: 3124–31.
122. You WC, Brown LM, Zhang L, et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst, 2006, 98: 974–83.
123. Take S, Mizuno M, Ishiki K, et al. The effect of eradicating helicobacter pylori on the development of gastric cancer in patients with peptic ulcer disease. Am J Gastroenterol, 2005, 100: 1037–42.
124. Rhead JL, Letley DP, Mohammadi M, et al. A new Helicobacter pylori vacuolating cytotoxin determinant, the intermediate region, is associated with gastric cancer. Gastroenterology, 2007, 133: 926–36.
125. Basso D, Zambon CF, Letley DP, et al. Clinical relevance of Helicobacter pylori cagA and vacA gene polymorphisms. Gastroenterology, 2008, 135: 91–9.
126. Yamaoka Y, Kato M, Asaka M. Geographic differences in gastric cancer incidence can be explained by differences between Helicobacter pylori strains. Intern Med, 2008, 47: 1077–83.
127. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med, 2001, 345: 784–9.
128. Byrd JC, Yan P, Sternberg L, et al. Aberrant expression of gland-type gastric mucin in the surface epithelium of Helicobacter pylori-infected patients. Gastroenterology, 1997, 113: 455–64.
129. Tulassay Z, Stolte M, Engstrand L, et al. Twelve-month endoscopic and histological analysis following proton-pump inhibitor-based triple therapy in Helicobacter pylori-positive patients with gastric ulcers. Scand J Gastroenterol, 2010, 45: 1048–58.
130. Yamada T, Miwa H, Fujino T, et al. Improvement of gastric atrophy after Helicobacter pylori eradication therapy. J Clin Gastroenterol, 2003, 36: 405–10.
131. Zhou L, Sung JJ, Lin S, et al. A five-year follow-up study on the pathological changes of gastric mucosa after H. pylori eradication. Chin Med J (Engl) , 2003, 116: 11–14.
132. Ley C, Mohar A, Guarner J, et al. Helicobacter pylori eradication and gastric preneoplastic conditions: a randomized, double-blind, placebo-controlled trial. Cancer Epidemiol Biomark Prev, 2004, 13: 4–10.
133. Salih BA, Abasiyanik MF, Saribasak H, et al. A follow-up study on the effect of Helicobacter pylori eradication on the severity of gastric histology. Dig Dis Sci, 2005, 50: 1517–22.
134. Lahner E, Bordi C, Cattaruzza MS, et al. Long-term follow-up in atrophic body gastritis patients: atrophy and intestinal metaplasia are persistent lesions irrespective of Helicobacter pylori infection. Aliment Pharmacol Ther, 2005, 22: 471 – 81.
135. Arkkila PE, Seppala K, Farkkila MA, et al. Helicobacter pylori eradication in the healing of atrophic gastritis: a one-year prospective study. Scand J Gastroenterol, 2006, 41: 782–90.
136. Toyokawa T, Suwaki K, Miyake Y, et al. Eradication of Helicobacter pylori infection improved gastric mucosal atrophy and prevented progression of intestinal metaplasia, especially in the elderly population: a long-term prospective cohort study. J Gastroenterol Hepatol, 2010, 25: 544–7.
137. Fukase K, Kato M, Kikuchi S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet, 2008, 372: 392–7.
138. Ogura K, Hirata Y, Yanai A, et al. The effect of Helicobacter pylori eradication on reducing the incidence of gastric cancer. J Clin Gastroenterol, 2008, 42: 279 – 83.
139. Takenaka R, Okada H, Kato J, et al. Helicobacter pylori eradication reduced the incidence of gastric cancer, especially of the intestinal type. Aliment Pharmacol Ther, 2007, 25: 805–12.
140. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol, 2008, 103: 2890–907.
141. Ford AC, Forman D, Bailey AG, et al. A community screening program for Helicobacter pylori saves money: 10-year follow-up of a randomized controlled trial. Gastroenterology, 2005, 129: 1910–17.
142. Hansen JM, Wildner-Christensen M, Hallas J, et al. Effect of a community screening for Helicobacter pylori: a 5-Yr follow-up study. Am J Gastroenterol, 2008, 103: 1106–13.
143. Rokkas T, Sechopoulos P, Pistiolas D, et al. Helicobacter pylori infection and gastric histology in first-degree relatives of gastric cancer patients: a meta-analysis. Eur J Gastroenterol Hepatol, 2010, 22: 1128–33.
144. Chen MJ, Wu DC, Ko YC, et al. Personal history and family history as a predictor of gastric cardiac adenocarcinoma risk: a case-control study in Taiwan. Am J Gastroenterol, 2004, 99: 1250–7.
145. Foschi R, Lucenteforte E, Bosetti C, et al. Family history of cancer and stomach cancer risk. Int J Cancer, 2008, 123: 1429–32.
146. Shin CM, Kim N, Yang HJ, et al. Stomach cancer risk in gastric cancer relatives: interaction between Helicobacter pylori infection and family history of gastric cancer for the risk of stomach cancer. J Clin Gastroenterol, 2010, 44: e34–9.
147. Blair V, Martin I, Shaw D, et al. Hereditary diffuse gastric cancer: diagnosis and management. Clin Gastroenterol Hepatol, 2006, 4: 262–75.
148. Niv Y, Hazazi R. Helicobacter pylori recurrence in developed and developing countries: meta-analysis of 13C-urea breath test follow-up after eradication. Helicobacter, 2008, 13: 56–61.
149. McColl KE. Clinical practice. Helicobacter pylori infection. N Engl J Med, 2010, 362: 1597–604.
150. 高文, 胡伏莲, 王晓敏. 含呋喃唑酮的四联疗法联合口腔洁治对幽门螺杆菌根除多次失败的补救治疗. 中华医学杂志, 2011, 91(29):836-839.
151. 梁浩,吴开春,杨云生, 等. 依卡倍特钠四联疗法根除幽门螺杆菌的临床试验:全国多中心临床研究. 中华化杂志, 2012, 3210(10):662-664.
152. Yi-Qi Du, Tun Su, Jian-Gao Fan, et al. Adjuvant probiotics improve the eradication effect of triple therapy for Helicobacter pylori infection. World J Gastroenterol, 2012, 21, 18(43): 6302-6307.
153. 胡伏莲, 成虹, 张学智,等. 多中心临床观察荆花胃康联合三联疗法治疔幽门螺杆菌相关性十二指肠溃疡和胃炎疔效及耐药分析. 中华医学杂志, 2012, 92(10): 679-684.
154. 温胃舒或养胃舒治疗幽门螺杆菌相关性慢性胃炎和消化性溃疡全国多中心临床研究协作组。王蔚虹,胡伏莲,成虹, 等. 温胃舒或养胃舒治疗幽门螺杆菌相关性慢性胃炎和消化性溃疡的全国多中心临床研究. 中华医学杂志, 2010, 90(2): 75-78.
155. 中华医学会消化病学分会.中国慢性胃炎共识意见.胃肠病学,2006,11(11):674-684.
156. 中华医学会消化病学分会. 中国慢性胃炎共识意见. 胃肠病学, 2013,18(1): 24-36.
157. 韩跃华,刘文忠,朱红音,等.上海地区幽门螺杆菌菌株iceA、babA2基因型与临床的关系.中华消化杂志,2004,24(6):322-325.
158. 李晓波,刘文忠,徐蔚文,等.上海地区幽门螺杆菌菌株cag致病岛基因cagA、cagE、cagT检出率及临床意义.中华消化杂志,2000,20(6):371-373.
159. Kodama M, Murakamik, Okimoto T, et al. The year prospective follow up of histological changes at five points on the gastric mucosa as recommended by the updated Sydney system after Helicobacter pylori eradication. J Gastroenterol, 2012, 47(4): 394-403.
160. 中国中西医结合学会消化系统疾病专业委员会.功能性消化不良的中西医结合诊疗共识意见(2010).中国中西医结合杂志,2011,31(11):1545-1549.

 

on 星期二 03月 27 by Soloman